Navigation Links
ImmuneRegen BioSciences Confirms Homspera's Therapeutic Anti-Influenza Effect on Pandemic H1N1 Influenza Virus After Oral Administration
Date:7/29/2009

SCOTTSDALE, Ariz., July 29 /PRNewswire-FirstCall/ -- ImmuneRegen BioSciences(R), a wholly owned subsidiary of IR BioSciences Holdings, Inc. (OTC Bulletin Board: IRBS), reports preliminary evidence that its selective Neurokinin 1-receptor agonist Homspera(R) is both active on oral administration and provides therapeutic effects against the current pandemic H1N1 virus infection.

Preliminary analysis of ongoing bioavailability studies in rats had revealed the oral administration of Homspera resulted in measurable amounts of the drug in lung tissue. Systemic absorption and accumulation in lungs was found after both oral and intra-duodenal administration in studies performed by a major, global contract research organization, with analytical work performed at MDx Bioanalytical Inc. of Tucson, Arizona.

Based on these findings, the Company commissioned H1N1 virus studies to be performed in the laboratories of a widely-respected University scientist. Using the accepted ferret model of H1N1 influenza virus infection, animals were treated orally (initially) with Homspera starting 24 hours following infection. While data collection and analysis is ongoing, preliminary evaluation of temperatures of infected ferrets reveals that orally-administered Homspera lessened the impact of influenza infection, resulting in shortened duration and more rapid resolution of the hyperthermia associated with infection.

Immune markers of infection remain to be assessed, but this pilot study apparently reveals that the ability of Homspera to attenuate symptoms of influenza virus infection, which have previously been reported in cotton rats infected with H3N2 influenza and in ferrets infected with H5N1 influenza, also extends to the current pandemic H1N1 strain.

These results, although preliminary, support the hypoth
'/>"/>

SOURCE ImmuneRegen BioSciences Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
2. ImmuneRegen Responds to Defense Threat Reduction Agency Request for Information
3. WaferGen Biosystems, ImmuneRegen BioSciences and University of Texas Southwestern Medical Center to Collaborate on Novel Wound Healing Research
4. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
5. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
6. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
7. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
8. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
9. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
10. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
11. Pressure BioSciences, Inc. Issued First Patent in Canada
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... 17, 2014 Based on the ... surgical imaging market is dominated by four major ... imaging market. These players include GE Healthcare (U.K.), ... (Germany). , Full Report Copy at ... Healthcare can be attributed to its strong product ...
(Date:12/17/2014)... 2014 Ipsen Biopharmaceuticals, Inc., an ... IPSEY), today announced that Somatuline® Depot® ... was approved by the U.S. Food and Drug ... tumors (GEP-NETs) in adult patients with unresectable, well ... to improve progression-free survival (PFS). , “The approval ...
(Date:12/17/2014)... (PRWEB) December 17, 2014 Xeno ... Excellence following its most recent COLA inspection. Xeno ... COLA, a national healthcare accreditation organization. Accreditation is ... of quality in day-to-day operations, demonstrate continued accuracy ... a rigorous on-site laboratory survey. , ...
(Date:12/17/2014)... -- Vermillion, Inc. (NASDAQ: VRML ), a bio-analytic ... next step in its expanded strategy to rebuild the ... naming of current Chief Operating Officer, Valerie Palmieri ... Chairman of the Board and CEO James LaFrance ... are effective January 1, 2015. "Jim and ...
Breaking Biology Technology:Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 2Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 3Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8Xeno Diagnostics Receives 3rd Award for Laboratory Excellence 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 3Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 4
... BOSTON, Sept. 8 PAREXEL International,Corporation (Nasdaq: ... updated its forward-looking financial guidance for the,first quarter ... and for the,full Fiscal Year, in conjunction with ... and other factors discussed herein., Josef von ...
... FREMONT, Calif., Sept. 8 Vermillion, Inc.,(Nasdaq: ... a,team of scientists at Stanford University and Vermillion has ... General Meeting of the,PAD Coalition. Led by Dr. John ... Scientific Officer at Vermillion, Inc., the research team,discovered a ...
... Appointments Strengthen Executive Team, FREMONT, Calif., Sept. ... company developing a novel transdermal,delivery technology, today announced ... and CEO. The company also announced several recent,appointments ... chief,operating officer and president; John M. Vuko, executive ...
Cached Biology Technology:PAREXEL International Updates Financial Guidance in Conjunction With the Acquisition of ClinPhone Plc and Other Factors 2PAREXEL International Updates Financial Guidance in Conjunction With the Acquisition of ClinPhone Plc and Other Factors 3PAREXEL International Updates Financial Guidance in Conjunction With the Acquisition of ClinPhone Plc and Other Factors 4PAREXEL International Updates Financial Guidance in Conjunction With the Acquisition of ClinPhone Plc and Other Factors 5Vermillion and Stanford Scientists Receive 'Best Research Award' From the PAD Coalition 2Vermillion and Stanford Scientists Receive 'Best Research Award' From the PAD Coalition 3Zosano Pharma, Inc. Announces Appointment of Gail Schulze as Chair and CEO 2Zosano Pharma, Inc. Announces Appointment of Gail Schulze as Chair and CEO 3Zosano Pharma, Inc. Announces Appointment of Gail Schulze as Chair and CEO 4
(Date:12/11/2014)... 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the addition ... Region 2015-2019"  report to their offering. ... is advances in technology. With continuous advances in ... to the latest standard that meets the needs ...
(Date:12/11/2014)... , Dec. 10, 2014  Data Sciences International ... has released a new series of digital telemetry ... toxicology researchers. M series, part of the PhysioTel™ ... the best possible physiologic data when incorporating functional ... functional endpoints to toxicology studies has evolved from ...
(Date:12/10/2014)... 9, 2014  Wake Forest Baptist Medical Center today announced ... School of Medicine. Funding for this $50 million capital ... will be publicly launched next summer. ... former 60 series R.J. Reynolds Tobacco Company complex, adjacent ... begin immediately with plans to be ready to welcome ...
Breaking Biology News(10 mins):Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2New telemetry implants expected to change how large animal toxicology studies are conducted 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
... Many ancient crustaceans went extinct following a massive collapse of ... suggests modern species living in rapidly declining reef habitats may ... appear in the November issue of Geology , the ... reefs and the number of decapod crustaceans, a group that ...
... exhaust particles from traffic pollution leads to increased asthma ... this is due to increased blood levels of IL-17A, ... children with high diesel exposure. , The study by ... online in the Journal of Allergy and Clinical ...
... of the American Association of Feline Practitioners (AAFP) ... patients based on risk assessment., From ... The American Association of Feline Practitioners, (AAFP) ... updated guidelines on appropriate feline vaccination schedules based ...
Cached Biology News:Fossil record shows crustaceans vulnerable as modern coral reefs decline 2Fossil record shows crustaceans vulnerable as modern coral reefs decline 3Appropriate vaccinations schedules for feline patients outlined 2
Human Cell Line Slides...
... 2 Detection System combines the indirect ... principle and Signets unique formulation of ... and reliablility. Signet reagents will achieve ... and automated protocols. ,Signets USA Detection ...
... Each Signet Level 2 Detection ... the avidin-biotin chemical bonding principle and ... to provide sensitivity, specificity and reliablility. ... immunostaining in both manual and automated ...
6X Loading Buffer is intended for gel electrophoresis of DNA fragments or PCR products....
Biology Products: